Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Hervé Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau
High-risk (HR) cytogenetics are associated with poor outcomes in newly diagnosed multiple myeloma (NDMM) and dedicated studies should address this difficult-to-treat population. The phase 2 study 2018-04 from the Intergroupe Francophone du Myelome evaluated feasibility of an intensive strategy with quadruplet induction and consolidation plus tandem transplant in HR transplant eligible (TE) NDMM (NCT03606577). HR cytogenetics were defined by the presence of del(17p), t(4;14) and/or t(14;16). Treatment consisted in daratumumab-carfilzomib-lenalidomide-dexamethasone (D-KRd) induction (6 cycles), autologous stem cell transplantation (ASCT), D-KRd consolidation (4 cycles), second ASCT, and daratumumab-lenalidomide maintenance for 2 years...
February 23, 2024: Blood
#2
JOURNAL ARTICLE
Qianshuang Geng, Jie Li, Xi Li, Wenjie Zhang, Guoxiang Zhang, Li Ge, Li Liang
RATIONALE: Nonsecretory multiple myeloma (NSMM) is a rare subtype of multiple myelom, occurring in 1% to 2% of multiple myelom and characterized by the inability of clonal plasma cells to synthesize or secrete immunoglobulins. We describe a 71-year-old male patient who began with bone pain and was referred to hospital several times, but was not properly diagnosed and effectively treated. PATIENT CONCERNS: A 71-year-old male patient visited our hematology department, complaining of lumbago for 1 year and back pain for half a year...
February 2, 2024: Medicine (Baltimore)
#3
REVIEW
C Benedikt Westphalen, Bernd J Krause, Markus Schuler, Sara Y Brucker, Andreas Hartkopf, Leo Rasche, Susanne Saußele, Bernhard Wörmann, Josef Hecken, Martin Danner
Die diesjährige Frühjahrstagung der DGHO (Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e. V.) stand unter der Überschrift «Herausforderungen in der Onkologie - personalisierte Therapiesteuerung». Über drei Themenkomplexe hinweg wurden aktuelle Möglichkeiten und Perspektiven der Therapiesteuerung in der Onkologie hinsichtlich «Methoden», gelungenen «Beispielen» sowie der «Umsetzung in der Versorgung» diskutiert.
2023: Oncology Research and Treatment
#4
JOURNAL ARTICLE
Mehdi Loukhnati, Fatima Ezzahra Lahlimi, Illias Tazi
Multiple myeloma is a hematologic malignancy characterized by clonal proliferation of plasma cells, mainly in bone marrow. Extramedullary disease is reported in many cases and may occur at diagnosis, at progression, or during relapse phase. Pericardial involvement is a rare condition that usually occurs with advanced-stage disease. We report a rare case of 76-year-old women with plasma cell-based pericardial effusion with cardiac tamponade as a form of presentation of multiple myeloma and discuss it in the light of literature...
June 13, 2023: Annales de Cardiologie et D'angéiologie
#5
JOURNAL ARTICLE
Suzanne Rowland, Robin Forbes, Doris Howell, Helen Kelly, Arta Taghavi Haghayegh, Maja Cardinale, Trisha Ramnanan, Samantha J Mayo
No abstract text is available yet for this article.
2023: Canadian Oncology Nursing Journal
#6
JOURNAL ARTICLE
Alexis Talbot, Arthur Bobin, Léa Tabone, Jérôme Lambert, Catherine Boccaccio, Cécile Deal, Marie-Odile Petillon, Olivier Allangba, Philippe Agape, Pierre Arnautou, Rakiba Belkhir, Sylvie Cailleres, Driss Chaoui, Marie-Lorraine Chrétien, Olivier Decaux, Samantha Schulmann, Laurent Frenzel, Lauris Gastaud, Antoine Huart, Cyrille Hulin, Lionel Karlin, Kamel Laribi, Ronan Le Calloch, Pascal Lenain, Margaret Macro, Salomon Manier, Lydia Montes, Stéphane Moreau, Philippe Moreau, Véronique Morel, James Norwood, Frédérique Orsini Piocelle, Aurore Perrot, Gian Matteo Pica, Philippe Rey, Anna Schmitt, Anne-Marie Stoppa, Mourad Tiab, Cyrille Touzeau, Valérie Vidal, Marguerite Vignon, Laure Vincent, Zoé Van De Wyngaert, Charles Zarnitsky, Naima Kerbouche, Prani Paka, Xavier Leleu, Bertrand Arnulf, Hervé Avet-Loiseau
Belantamab mafodotin (BM) is an anti-BCMA antibody-drug conjugate (GSK2857916) that represents an alternative option in multiple myeloma. We sought to assess the efficacy and safety in real-world of BM in patients who benefited from an early access program. We conducted an observational, retrospective, multicenter study. Eligibility criteria were treatment of relapsed or refractory multiple myeloma (RRMM) in monotherapy in adult patients who have received at least 3 lines of therapy previously, including at least one immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody, and whose disease progressed during the last treatment period...
April 20, 2023: Haematologica
#7
Baran Khalil, Laura Parzer, Sigrid Machherndl-Spandl, Sophie Haitchi-Petnehazy, Katharina Etmajer, Karl Haas, Peter Reinelt
No abstract text is available yet for this article.
April 19, 2023: Ophthalmologie
#8
JOURNAL ARTICLE
J Torbey, M Adler, S Abramowicz, F Willermain
No abstract text is available yet for this article.
April 13, 2023: Journal Français D'ophtalmologie
#9
JOURNAL ARTICLE
Thomas Matthes, Peter Jandus
Infections are among the leading causes of morbidity and mortality in lymphoproliferative malignancies such as multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). The causes of infections are often multifactorial and may be due to disease- or treatment-related factors. New therapies have improved survival in lymphoproliferative malignancies, resulting in an increased incidence of secondary immune deficiencies (SID) in these diseases.
April 5, 2023: Revue Médicale Suisse
#10
JOURNAL ARTICLE
Baran Khalil, Laura Parzer, Sigrid Machherndl-Spandl, Sophie Haitchi-Petnehazy, Katharina Etmajer, Karl Haas, Peter Reinelt
No abstract text is available yet for this article.
February 27, 2023: Ophthalmologie
#11
REVIEW
Mélanie Try, Stéphanie Harel
Renal impairment is common during multiple myeloma and persistent reduction in kidney function strongly affects prognosis. Cast nephropathy, by monoclonal free light chains precipitation with uromodulin in renal tubules, is the main cause of acute kidney injury in multiple myeloma. Kidney biopsy, although not necessary for diagnosis, allows assessment of renal prognosis according to the extent of cast formation, tubular atrophy and interstitial fibrosis. Prevention and early diagnosis of acute kidney injury are essential to optimize management and avoid progression to chronic kidney disease...
February 7, 2023: Bulletin du Cancer
#12
JOURNAL ARTICLE
Charles Dumontet, Delphine Demangel, Perrine Galia, Lionel Karlin, Laurent Roche, Mathieu Fauvernier, Camille Golfier, Marie-Charlotte Laude, Xavier Leleu, Philippe Rodon, Murielle Roussel, Isabelle Azaïs, Chantal Doyen, Borhane Slama, Salomon Manier, Olivier Decaux, Maroulio Pertesi, Marie Beaumont, Denis Caillot, Eileen M Boyle, Manuel Cliquennois, Pascale Cony-Makhoul, Anne-Violaine Doncker, Véronique Dorvaux, Marie Odile Petillon, Jean Fontan, Bénédicte Hivert, Isabelle Leduc, Cécile Leyronnas, Margaret Macro, Michel Maigre, Clara Mariette, Philippe Mineur, Sophie Rigaudeau, Bruno Royer, Laure Vincent, James Mckay, Emeline Perrial, Laurent Garderet
Familial forms of monoclonal gammopathy, defined as multiple myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS), are relatively infrequent and most series reported in the literature describe a limited number of families. MM rarely occurs in a familial context. MGUS is observed much more commonly, which can in some cases evolve toward full-blown MM. Although recurrent cytogenetic abnormalities have been described in tumor cells of sporadic cases of MM, the pathogenesis of familial MM remains largely unexplained...
January 1, 2023: American Journal of Hematology
#13
JOURNAL ARTICLE
Lilli Sophie Sester, Hartmut Goldschmidt, Sirka Nitschmann
No abstract text is available yet for this article.
February 2023: Inn Med (Heidelb)
#14
JOURNAL ARTICLE
Mirjam Marjolein Garvelink, Kirsten Daniels, Okke de Weerdt, Paul Bastiaan van der Nat
OBJECTIVE: A next step in value-based healthcare (VBHC) is to use outcome information (OI) to inform patients about (personalized) outcomes of care in order to support decision-making processes. We aimed to explore multiple myeloma (MM) patients' and caregivers' views on communication of OI and (shared) decision-making (SDM). METHODS: Focus groups with MM patients and caregivers. Main topics were experiences and needs with information provision, communication, decision-making, and use of OI...
December 1, 2022: Zeitschrift Für Evidenz, Fortbildung und Qualität Im Gesundheitswesen
#15
JOURNAL ARTICLE
Hongying You, Song Jin, Chunxiao Wu, Qingqing Wang, Shuang Yan, Weiqin Yao, Xiaolan Shi, Jingjing Shang, Lingzhi Yan, Ying Yao, Jing Wang, Panfeng Wang, Jinlan Pan, Depei Wu, Chengcheng Fu
OBJECTIVE: 1q21 gain/amplification (1q21+) is a common abnormal karyotype in multiple myeloma, and its proportion in Chinese patients is much higher. If 1q21+ is included as one of the poor prognostic factors, it will greatly increase the proportion of high-risk patients in newly diagnosed multiple myelome (NDMM) patients. Therefore, the poor prognostic significance of 1q21+ is still controversial. This study mainly analyzed the clinical characteristics, treatment response and prognostic significance of 1q21+ in NDMM patients...
2022: Frontiers in Oncology
#16
JOURNAL ARTICLE
Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients.
Anais Schavgoulidze, Valerie Lauwers-Cances, Aurore Perrot, Titouan Cazaubiel, Marie-Lorraine Chretien, Philippe Moreau, Thierry Facon, Xavier Leleu, Lionel Karlin, Anne-Marie Stoppa, Olivier Decaux, Karim Belhadj, Bertrand Arnulf, Mohamad Mohty, Clara M Ariette, Cecile Fohrer-Sonntag, Pascal Lenain, Jean-Pierre Marolleau, Mourad Tiab, Carla Araujo, Frederique Orsini-Piocelle, Arnaud Jaccard, Murielle Roussel, Lotfi Benboubker, Jean-Richard Eveillard, Mamoun Dib, Marion Divoux, Michel Attal, Herve Avet-Loiseau, Jill Corre
In the era of personalized treatment in multiple myeloma, high-risk patients must be accurately defined. The International Myeloma Working Group recommends using the Revised International Staging System (R-ISS) to identify high-risk patients. The main purpose of our work was to explore the heterogeneity of outcome among R-ISS stage II patients assessing the impact of ISS, chromosomal abnormalities (CA) and LDH level in this subgroup. Data were issued from 1,343 newly diagnosed myeloma patients up to 65 years, enrolled in 3 clinical trials implemented by the Intergroupe Francophone du Myelome...
September 29, 2022: Haematologica
#17
JOURNAL ARTICLE
F Gilles
Multiple myeloma is one of the most frequent hematological malignancies in the elderly and corresponds to the presence of a plasma cell clone. Antitumor treatment combines different therapeutics, including alkylating agents, high-dose corticosteroids, immunomodulators and proteasome inhibitors. These treatments can have cardiovascular side effects that are important to be aware of. The role of the cardiologist is essential in preventing, detecting and managing these effects properly in order to improve the cardiological and oncological prognosis of patients...
August 10, 2022: Annales de Cardiologie et D'angéiologie
#18
JOURNAL ARTICLE
Julian Zimmermann, E Esser, N Eter, P Schütt, C E Uhlig
No abstract text is available yet for this article.
August 9, 2022: Ophthalmologie
#19
JOURNAL ARTICLE
Aboubacar Sidiki Fofana, Christophe Bouaka, Ghassan Alchahin, Simona Dorina Boncila, Magara Samaké, Seydou Sy, Hamadoun Yattara, Saharé Fongoro, Julia Torrents, Rolande Cohen Valensi, Delphine Haussaire
INTRODUCTION: Lenalidomide is an immunomodulatory drug widely used in the treatment of multiple myeloma. Several cases of nephrotoxicity have been reported, but few have been documented histologically. CASE PRESENTATION: We report a case of acute interstitial nephritis to lenalidomide in a 62-year-old patient with multiple myeloma after administration of the second course of chemotherapy according to the protocol combining bortezomib, lenalidomide and dexamethasone...
July 29, 2022: Néphrologie & Thérapeutique
#20
JOURNAL ARTICLE
Ekaterina Sokolenko, Patricia Johansson, Saskia Ting, Nikolaos E Bechrakis, Miltiadis Fiorentzis
This case illustrates clinical, histopathological, immunohistochemical, and molecular pathological diagnostic testing of smoldering myeloma with atypical ophthalmic manifestations. In our case, the choroidal lesion presented as a solitary manifestation of a systemic disease. Choroidal lesions of monoclonal plasma cells are extremely rare and should be included in the differential diagnosis of amelanotic choroidal lesions, even if the histopathological examination of the primary lesion is not informative. Clinical course, immunohistochemistry, and molecular pathology are essential components of the diagnostic pathway...
July 28, 2022: Klinische Monatsblätter Für Augenheilkunde
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
